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OBJECTIVE: To evaluate the effect of spironolactone on ventricular stiffness in spontaneously hypertensive adult
rats subjected to high salt intake.
INTRODUCTION: High salt intake leads to cardiac hypertrophy, collagen accumulation and diastolic dysfunction.
These effects are partially mediated by cardiac activation of the renin-angiotensin-aldosterone system.
METHODS: Male spontaneously hypertensive rats (SHRs, 32 weeks) received drinking water (SHR), a 1% NaCl
solution (SHR-Salt), or a 1% NaCl solution with a daily subcutaneous injection of spironolactone (80 mg.kg
-1) (SHR-
Salt-S). Age-matched normotensive Wistar rats were used as a control. Eight weeks later, the animals were
anesthetized and catheterized to evaluate left ventricular and arterial blood pressure. After cardiac arrest, a double-
lumen catheter was inserted into the left ventricle through the aorta to obtain in situ left ventricular pressure-
volume curves.
RESULTS: The blood pressures of all the SHR groups were similar to each other but were different from the
normotensive controls (Wistar = 109¡2; SHR = 118¡2; SHR-Salt = 117¡2; SHR-Salt-S = 116¡2 mmHg; P,0.05).
The cardiac hypertrophy observed in the SHR was enhanced by salt overload and abated by spironolactone (Wistar
= 2.90¡0.06; SHR = 3.44¡0.07; SHR-Salt = 3.68¡0.07; SHR-Salt-S = 3.46¡0.05 mg/g; P,0.05). Myocardial
relaxation, as evaluated by left ventricular dP/dt, was impaired by salt overload and improved by spironolactone
(Wistar = -3698¡92; SHR = -3729¡125; SHR-Salt = -3342¡80; SHR-Salt-S = -3647¡104 mmHg/s; P,0.05).
Ventricular stiffness was not altered by salt overload, but spironolactone treatment reduced the ventricular stiffness
to levels observed in the normotensive controls (Wistar = 1.40¡0.04; SHR = 1.60¡0.05; SHR-Salt = 1.67¡0.12; SHR-
Salt-S = 1.45¡0.03 mmHg/ml; P,0.05).
CONCLUSION: Spironolactone reduces left ventricular hypertrophy secondary to high salt intake and ventricular
stiffness in adult SHRs.
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INTRODUCTION
High salt intake promotes the elevation of blood pressure,
cardiac hypertrophy, the impairment of left ventricular
relaxation, endothelial dysfunction and kidney injury.
1-9
Spontaneously hypertensive rats (SHRs) are the most
frequently used animal model of essential hypertension in
humans. This rat strain is more susceptible to cardiac
damage when a high salt diet is introduced early in life.
10,11
Increased salt intake induces cardiac fibrosis and hyper-
trophy that may contribute to impair cardiac function
independent of blood pressure.
1,12,13 For example, salt over-
load increases left ventricular hypertrophy two-fold, as
evaluated by cardiac weight, in 7-week-old SHRs.
14 Simi-
larly, Ziegelho ¨ffer-Mihalovicova et al.
15 have shown that
12-week-old SHRs develop cardiac hypertrophy when
subjected to high salt intake. High-salt diets decrease
plasma aldosterone levels, but increase its production in
the heart.
16,17 Aldosterone contributes to ventricular remo-
deling in some pathological conditions by increasing
collagen synthesis
2,4,18,19 and by modifying endothelial
and vascular functions.
20
Mineralocorticoid antagonists induce beneficial changes
in left ventricular remodeling and prevent or partially
reverse cardiac fibrosis and pathological hypertrophy that
contribute to the development of diastolic heart fail-
ure.
18,21,22 For example, in young normotensive Wistar rats,
a high-salt diet increases interstitial and perivascular
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477fibrosis in the heart and also induces myocyte hypertrophy.
These effects are suppressed by spironolactone treatment,
which suggests that aldosterone may mediate salt-induced
myocardial damage.
23 Accordingly, aldosterone receptor
blockade reduces cardiac fibrosis and vascular remodeling
in salt-loaded stroke-prone SHRs,
22 reduces left ventricular
hypertrophy and improves coronary flow in young SHRs
subjected to high salt intake.
14
However, the majority of studies that have investigated
the effect of salt overload in hypertensive rats were carried
out in young animals.
2,3,4,16,22 These animals had a short
exposure time to the pressure overload; consequently, left
ventricle remodeling may have been incomplete.
24-26 This
scenario may explain the confusion surrounding the origin
of left ventricular hypertrophy and stiffness. These changes
may be secondary to pressure or salt overload. However,
the effects of salt overload in fully remodeled adult
hypertensive rats remain unknown. Therefore, the aim of
this study was to investigate the effects of high-salt intake in
an adult animal model with established hypertensive heart
disease and to test the effect of spironolactone on left
ventricular hypertrophy and stiffness.
MATERIALS AND METHODS
Animals and experimental groups
Animals were acquired from the Federal University of
Espı ´rito Santo. All of the protocols in this study were in
accordance with the Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 85-23, revised
1996) and the Ethical Principles in Animal Experimentation
of the Brazilian College of Animal Experimentation
(COBEA) and were approved by the institutional Com-
mittee of Ethics on Animal Research (N. 012/2010).
Adult male SHRs (32 weeks) were randomly assigned
to receive only drinking water (hypertensive control, SHR,
n=8), 1% NaCl solution in drinking water (SHR-Salt, n=9),
or 1% NaCl solution with daily subcutaneous spironolac-
tone (80 mg.kg
-1) administration (SHR-Salt-S, n=9). Age-
matched Wistar rats were used as normotensive controls.
The spironolactone dose (80 mg.kg
-1) has been previously
demonstrated to have beneficial effects on the heart without
significantly altering blood pressure in SHRs.
27
Hemodynamic evaluation
After 8 weeks in the study protocol, the animals were
anesthetized with ketamine (70 mg.kg
-1, i.p., Agener Unia ˜o,
Brazil) and xylazine (10 mg.kg
-1, ip, Bayer, Brazil) for left
ventricle catheterization. Briefly, the right common carotid
artery was separated from connective tissue and catheterized
with a fluid-filled polyethylene catheter (P50). The catheter
was connected to a pressure transducer (TRI 21, Letica
Scientific Instruments, Spain) and then to a digital system
(Powerlab/4SP ML750, ADInstruments, Australia). After
arterial systolic and diastolic blood pressure were recorded,
the catheter was advanced to the left ventricle to obtain the
followingparameters:heartrate (HR),left ventricularsystolic
pressure (LVSP), end-diastolic pressure (LVEDP), and the
maximum rate of pressure rise (+dP/dt) and fall (-dP/dt).
Measurement of the in situ left ventricular
pressure-volume relationship
After hemodynamic measurements, the heart was
arrested with 3 M KCl (0.2 ml, iv), and a double lumen
catheter (P50 inserted into P200) was inserted into the left
ventricle through the aorta to determine the in situ left
ventricle diastolic pressure-volume relationship, as pre-
viously described.
28 Briefly, the atrio-ventricular groove was
occluded, and a small incision was made in the free wall of
the right ventricle to hinder any compressor effect. A
sodium chloride solution (0.9%) was infused with an
infusion pump (BI 200, Insight Equipments, Brazil) at a
constant rate of 0.60 mL.min
-1 into the P200. Pressure was
continuously monitored through the P50. Three curves were
recorded in each heart over ten minutes. The obtained
curves were segmented and then separately analyzed.
Pressure follows a linear pattern from 0 to 5 mmHg during
volume infusion, and the slope is indicative of left
ventricular dilatation. For the 5 to 30 mmHg segment, the
curve was adjusted to a monoexponential model. Thus, to
determine the stiffness constant during the 5-30 mmHg
interval, a logarithmic transformation was performed on the
pressure scale to create a linear fit. The slope of this
regression represents the stiffness constant.
After pressure-volume readings were recorded, the heart
was excised, and the chambers were separated and
weighed. The lungs and kidney were also weighed.
Statistical analysis
Data are shown as mean ¡ standard error of the mean
(SEM). Comparisons between means were assessed using
one-way analysis of variance (ANOVA) followed by the
Fischer post-hoc test, when appropriate. Linear regression
was used to acquire the slope of each segment (dilatation
and stiffness constants) of the pressure-volume curve. All
statistical analyses were performed with the SPSS 13.0




All of the animals survived the entire treatment period. At
baseline, all of the SHR groups had similar body weights
but were significantly different from the age-matched
Wistar rats (Wistar = 585¡6 g; SHR = 310¡7 g; SHR-
Salt = 315¡5 g; SHR-Salt-S = 317¡4g ;P,0.05). However,
after 8 weeks, the mean body weight of the SHR-Salt group
was higher than in the other SHR groups (Wistar =
596¡6 g; SHR = 330¡5 g; SHR-Salt = 343¡6 g; SHR-
Salt-S = 331¡4g ;P,0.05).
Table 1 shows the morphometric parameters observed
after 8 weeks of treatment. Cardiac hypertrophy, as
evaluated by crude ventricular weight, was higher in
SHR-Salt group, and normalized in the SHR-SALT-S group.
In addition, when cardiac weight was corrected for body
weight, the ventricular hypertrophy observed in the salt-
loaded SHRs was abated by spironolactone treatment. No
differences were found among the groups in the other
morphological parameters (i.e., the weight of lungs and
kidney, see Table 1).
Hemodynamic evaluation
Hemodynamic variables are displayed in Table 2. Heart
rate did not vary significantly among the groups. Arterial
and left ventricular pressure were measured in anesthetized
animals. In this condition, the blood pressure shows lower
values as compared to awake animals, mainly in SHRs. The
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478systolic blood pressure was higher in all SHR groups than in
the Wistar control group, though there were no significant
differences among the SHR groups (Wistar =
109¡2 mmHg; SHR = 118¡2 mmHg; SHR-Salt =
117¡2 mmHg; SHR-Salt-S = 116¡2 mmHg). The diastolic
blood pressure was similar in all groups (Table 2).
Left ventricular catheterization showed that the left
ventricular systolic pressure was higher in the SHR groups
than in the Wistar rats and that neither salt load nor
spironolactone changed this parameter. However, the
maximum left ventricle relaxation rate, -dP/dt, was reduced
in the SHR-Salt group, and spironolactone hindered this
effect (Table 2).
Pressure-volume curve
The pressure-volume curve (Figure 1A) was divided into
two segments: an initial linear segment that represents the
dilatation constant (K1) (Figure 1B) and an exponential
segment that indicates left ventricular stiffness (K2)
(Figure 1C).
Left ventricular dilatation was similar in all groups, but a
trend toward higher values in the SHR-Salt-S group relative
to the Wistar rats (Wistar = 0.71¡0.05 mmHg/ml; SHR =
0.68¡0.04 mmHg/ml; SHR-Salt = 0.69¡0.05 mmHg/ml;
SHR-Salt-S = 0.65¡0.03 mmHg/ml; P=0.09; Figure 1B)
was observed, which suggests that neither salt overload nor
spironolactone significantly changed the left ventricular
volume. However, compared to the Wistar rats, the
untreated SHR group showed increased ventricular stiff-
ness, but interestingly, high salt intake did not alter this
parameter. Moreover, in spironolactone-treated rats, left
ventricular stiffness was reduced to a level similar to that
found in Wistar rats (Wistar = 1.40¡0.04 mmHg/ml; SHR
= 1.60¡0.05 mmHg/ml; SHR-Salt = 1.67¡0.12 mmHg/ml;
SHR-Salt-S = 1.45¡0.03 mmHg/ml; P,0.05; Figure 1C).
DISCUSSION
Our study shows that chronic high salt intake enhances
cardiac hypertrophy in adult SHRs. However, left ventri-
cular stiffness was not affected by salt overload.
Interestingly, treatment with spironolactone reduced left
ventricular hypertrophy and improved left ventricular
compliance.
It is well known that SHRs have high blood pressure at
two months of age. As a result, cardiac hypertrophy
develops early and reaches a stable value around three
months of age, remaining constant throughout the rest of
the life of the animal.
25,26 Our study shows that high salt
intake increases cardiac hypertrophy in adult SHRs that had
well-established blood pressure levels and compensatory
cardiac hypertrophy compared to normotensive rats.
Conversely, we did not observe an increase in the blood
pressure of adult SHRs subjected to high salt intake. It is
important to note that the hemodynamic evaluation was
carried out under anesthesia, which is known to consider-
ably reduce blood pressure levels.
29,30
Some reports have shown that high salt intake increases
left ventricular hypertrophy.
1,31,32 Additionally, others have
shown that this effect is related to salt-induced hyperten-
sion.
1,32 However, this view is not unanimous. Matavelli et
al.
16 have shown that independent of high blood pressure, a
high-salt diet leads to left ventricular hypertrophy as well as
some other detrimental hemodynamic effects in SHRs.
Moreover, in normotensive rats, a high-salt diet does not
increase blood pressure even when there is significant
cardiac hypertrophy.
33 Our data are in agreement with the
Table 1 - Morphometric parameters measured after eight weeks of treatment.
Wistar SHR SHR-Salt SHR-Salt-S
Animals (n) 9899
Ventricles (g) 1.42¡0.03 1.14¡0.03* 1.24¡0.03*{ 1.15¡0.02*{
Ventricles/BW (mg/g) 2.90¡0.06 3.44¡0.07* 3.68¡0.07*{ 3.46¡0.05*{
Lungs (g) 3.10¡0.09 2.59¡0.10* 2.62¡0.11* 2.72¡0.10*
Lungs/BW (mg/g) 6.10¡0.2 7.85¡0.3* 7.64¡0.3* 8.21¡0.3*
Lungs H2O(%) 80.8¡0.3 81.2¡0.3 80.4¡0.4 80.3¡0.3
Kidney (g) 2.91¡0.06 2.52¡0.05* 2.61¡0.05* 2.56¡0.04*
Kidney/BW (mg/g) 6.71¡0.11 7.65¡0.12* 7.61¡0.06* 7.72¡0.09*
Data are presented as the mean¡SEM
*P,0.05 vs Wistar; { P,0.05 vs SHR; { P,0.05 vs SHR-Salt
Table 2 - Hemodynamic parameters observed in anesthetized animals after eight weeks of treatment.
Wistar SHR SHR-Salt SHR-Salt-S
Animals (n) 98 9 9
HR (BPM) 192¡8 190¡7 183¡7 187¡7
SBP (mmHg) 109¡2 118¡2* 117¡2* 116¡2*
DBP (mmHg) 76¡37 9 ¡27 5 ¡37 7 ¡2
LVSP (mmHg) 113¡2 121¡2* 123¡2* 119¡2*
LVEDP (mmHg) 4.1¡0.3 6.3¡0.3* 6.8¡0.6* 6.6¡0.5*
+dP/dt (mmHg/s) 4854¡101 4794¡86 4737¡103 4536¡114
-dP/dt (mmHg/s) -3698¡92 -3729¡125 -3342¡80*{ -3647¡104{
Data are presented as the mean¡SEM. * P,0.05 vs Wistar; { P,0.05 vs SHR; { P,0.05 vs SHR-Salt
HR: heart rate, SBP: systolic blood pressure, DBP: diastolic blood pressure, LVSP: left ventricular systolic pressure, LVEDP: left ventricular end-diastolic
pressrue, dP/dt: maximum rate of pressure rise and fall.
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479hypothesis that cardiac hypertrophy is induced by salt
overload independent of increased blood pressure, even
when hypertension-induced hypertrophy is already fully
established.
The hypertrophic response mediated by high salt intake
was ameliorated by the co-administration of spironolactone.
This result is similar to other reports in which high-salt diet-
induced cardiac hypertrophy in normotensive rats was
inhibited by spironolactone.
23,33 Comparatively, cardiac
hypertrophy in SHRs subjected to high salt intake was not
reversed by an angiotensin-converting enzyme inhibitor, a
beta-blocker or a calcium antagonist.
15 This supports the
idea that cardiac hypertrophy mediated by salt overload
may be induced, at least in part, directly by tissue
aldosterone production, independently from the action of
angiotensin II. However, it was demonstrated by Varagic
et al.
32 that blocking the AT1 receptor reduces cardiac
hypertrophy without affecting blood pressure in young salt-
loaded SHRs. In salt-overloaded rats, eplerenone reduces
left ventricular hypertrophy without affecting blood pres-
sure.
34 Similarly, in hypertensive humans, an aldosterone
antagonist improves diastolic function independent of any
reduction in blood pressure or cardiac mass, indicating that
this drug may be acting directly on the myocardium.
35
Furthermore, the reduction in cardiac hypertrophy was not
related to any potential antihypertensive effect of spirono-
lactone because, as we have shown, blood pressure levels
were similar in all the SHR groups.
Left ventricular hypertrophy is an increase in myocardial
mass that leads to a structural rearrangement of the
components of the ventricular wall and may result in
ventricular stiffening, thereby compromising systolic and
diastolic function.
36,37 Analysis of the passive pressure-
volume curve confirms that SHRs have increased left
ventricular wall stiffness when compared to normotensive
rats. Surprisingly, adult SHRs (8 months) subjected to high
salt intake did not show an additional increase in left
ventricular stiffness. This may be because the heart is
already remodeled and has stable levels of left ventricular
hypertrophy and interstitial fibrosis.
38
In young SHRs, it has been reported that salt overload
leads to interstitial and perivascular fibrosis.
1,2,32 In turn,
fibrosis is related to enhanced left ventricular stiffness,
which leads to impairment in left ventricle relaxation.
38 In
this study, we observed that high salt intake led to a
reduction of cardiac -dP/dt, suggesting that relaxation was
impaired. It has recently been reported that salt overload
leads to diastolic dysfunction in rats with metabolic
syndrome.
7 However, it has been shown that in 8 week-
old SHRs a high-salt diet increases ventricular fibrosis.
4
However, in 6 month-old SHRs, a high-salt diet does not
alter type I or III collagen mRNA expression in the left
ventricle.
15 We did not observe an increase in ventricular
stiffness in adult SHRs subjected to high salt intake. This
response reinforces our hypothesis that the adult SHRs used
in this study have well-established left ventricular remodel-
ing (i.e., cardiac hypertrophy and extracellular matrix
remodeling). Ten month-old SHRs display extensive cardiac
hypertrophy and well-established life of the animal.
38 The
reduction in -dP/dt observed could be associated with the
Figure 1 - Left ventricular in situ pressure-volume curve normalized for body weight (A). The chamber dilatation was obtained from the
first segment (0 to 5 mmHg) of the curve (B). The chamber stiffness was obtained from the second segment (5 to 30 mmHg) of the curve
(C) when plotted on a log scale. Data are presented as the mean¡SEM. * P,0.05 vs Wistar; { P,0.05 vs SHR; { P,0.05 vs SHR-Salt
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480first stages of diastolic dysfunction because hemodynamic
parameters were unchanged, indicating that the rats have
compensated for pressure overload.
We have demonstrated that spironolactone-treated SHRs
had preserved left ventricular -dP/dt and better compliance
when compared to other SHR groups. It is well known that
aldosterone directly activates collagen production and
deposition in the heart.
39 This effect increases left ventri-
cular stiffness and leads to diastolic dysfunction.
40 It has
been demonstrated that spironolactone reduces myocardial
fibrosis in cardiac hypertrophy in animals and humans.
41 In
1-year-old SHRs, eplerenone reduces left ventricular fibrosis
and improves coronary hemodynamics.
42 In the clinical
setting, spironolactone improves diastolic dysfunction and
reduces left ventricular stiffness in elderly or dilated
cardiomyopathic patients.
43,44 Thus, it is possible that the
anti-fibrotic and anti-hypertrophic effects of spironolactone
could be the main cause for the amelioration of left
ventricular compliance observed in SHRs.
The absence of non-invasive blood pressure measure-
ments is a limitation of our study. Additionally, we cannot
rule out the possibility that high salt intake and/or
spironolactone significantly changed blood pressure
because we did not test a spironolactone-treated group that
was not exposed to high salt intake. Moreover, the possible
hypotensive effect of spironolactone cannot be discarded
even though it has been reported that the dose of
spironolactone (80 mg.kg
-1) used in our study is not
associated with a reduction in blood pressure.
27
CONCLUSIONS
Using an adult hypertensive-rat model, we demonstrated
that a high-salt diet leads to left ventricular hypertrophy
and impairs left ventricular relaxation. In addition, miner-
alocorticoid receptor blockade with spironolactone amelio-
rates salt-induced cardiac dysfunction and hypertrophy and
also reduces the left ventricular stiffness observed in adult
SHRs. These results reinforce the idea that high-salt diets
are deleterious to cardiovascular function and that aldoster-
one is, at least in part, involved in these effects.
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